Triazolam, ZPD, MPD, and MDF were purchased from Sigma (St. Louis, MO, USA). TCS-1102 was purchased from Tocris (Bristol, UK). PML was purchased from Tokyo Kasei (Tokyo, Japan). These compounds were dissolved in dimethyl sulfoxide (Nacalai, Kyoto, Japan) to make stock solutions.
Triazolam
Manufactured by Merck Group
Sourced in United States
Triazolam is a laboratory equipment product manufactured by Merck Group. It is a chemical compound used in various scientific and research applications. The core function of Triazolam is to serve as a research tool for analysis and experimentation, but no further details on its intended use can be provided in an unbiased and factual manner.
Automatically generated - may contain errors
Lab products found in correlation
Dimethyl sulfoxide (dmso), by Nacalai Tesque (1 mentions)
Tcs 1102, by Bio-Techne (1 mentions)
Clonazepam, by Merck Group (1 mentions)
Progesterone, by Bio-Techne (1 mentions)
Ganaxolone, by Bio-Techne (1 mentions)
Finasteride, by Bio-Techne (1 mentions)
Alphaxalone, by Bio-Techne (1 mentions)
Midazolam, by Henry Schein (1 mentions)
Midazolam, by Pfizer (1 mentions)
Pregnanolone, by Bio-Techne (1 mentions)
Dora 22, by Merck Group (1 mentions)
Flumazenil, by Merck Group (1 mentions)
5 protocols using triazolam
1
Evaluation of Novel Compounds
2
Steroid and Benzodiazepine Preparation Protocol
3
Drug Combination Preparation for Behavioral Studies
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Midazolam (Hospira Inc., Lake Forest, IL, United States) 5 mg/ml pharmaceutical stock was diluted with 0.9% saline solution. Triazolam (Sigma-Aldrich, St. Louis, MO, United States) was dissolved in propylene glycol and diluted with sterile water to a 50% propylene glycol/50% sterile water solution. Pregnanolone (Tocris Bioscience, Bristol, United Kingdom) was dissolved in a 45% (w/v) 2-hydroxypropyl-β-cyclodextrin solution. Triazolam-Pregnanolone combinations for the self-administration study were prepared by dissolving each drug separately at twice the concentration of the test dose. The separate solutions were then combined in a single syringe prior to test sessions to create the test combination. Triazolam-Pregnanolone combinations for the observation study were prepared by dissolving each drug separately and then administered sequentially via the i.v. catheter. In these sessions, the test dose of Triazolam was administered first, followed by the test dose of Pregnanolone.
4
Hypnotic Drug Efficacy Evaluation in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All pharmacological agents were diluted in 20% d-alpha tocopherol polyethylene glycol 1,000 succinate (Vitamin E-TPGS) vehicle to a dose volume of 0.1 ml/10 g, and were administered orally using standard stainless steel gavage needles affixed to a 1 ml syringe (p.o.). Hypnotics tested included a DORA-22 (100 mg/kg; Gotter et al., 2014 (link); a kind gift from Merck & Co., Inc., Kenilworth, NJ, USA), triazolam (1.25 mg/kg; Sigma-Aldrich Corporation, St. Louis, MO, USA), and eszopiclone (15 mg/kg; Carbosynth Ltd., Compton, Berkshire, UK). Doses were determined according to previously published articles (Gotter et al., 2014 (link)) and clinical dosage information for humans (10 mg for suvorexant, a derivative of DORA-22, 0.125 mg for triazolam, and 1 mg for eszopiclone).
All mice received treatment with all drugs/vehicle in randomized order. An interval between administrations of at least 3 days was used according to the previous article (Winrow et al., 2012 (link)) to prevent any possible influences of repeated procedures and residual drug effects. Half-life off-rate of DORA-22 to orexin 2 receptor binding was reported to be 37.8 min (Gotter et al., 2013 (link)) and no next-day effects was reported at least in monkeys (Gotter et al., 2013 (link)).
All mice received treatment with all drugs/vehicle in randomized order. An interval between administrations of at least 3 days was used according to the previous article (Winrow et al., 2012 (link)) to prevent any possible influences of repeated procedures and residual drug effects. Half-life off-rate of DORA-22 to orexin 2 receptor binding was reported to be 37.8 min (Gotter et al., 2013 (link)) and no next-day effects was reported at least in monkeys (Gotter et al., 2013 (link)).
5
Pharmacological Modulation of GABA-A Receptors
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!